Where Is OxyContin Abuse Deterrent Data? Purdue Has Sent Two Studies, But Wait Continues
US FDA expects to receive two more postmarket studies this year, but Purdue has not yet decided if it will resubmit a supplemental NDA. Consortium of 13 companies have completed six additional studies on extended-release opioids.
